Dankner, Matthew <br/><br/>
Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'.  [electronic resource] 

 -  British journal of cancer  05 2018 
 - 1276-1277 p.  digital 
<br/><br/> Publication Type: Letter; Comment 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/s41416-018-0012-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal<br/>Biomarkers<br/>Cetuximab<br/>Colorectal Neoplasms<br/>ErbB Receptors--genetics<br/>Genomics<br/>Humans<br/>Mutation<br/>Proto-Oncogene Proteins B-raf--genetics